Navigation Links
Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
Date:1/6/2009

ROCKVILLE, Md., Jan. 6 /PRNewswire-USNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today that SQ109, its lead drug candidate for the treatment of tuberculosis (TB), was the first drug approved for evaluation in a newly awarded clinical program contract to Dynport Vaccine Company LLC and Quintiles Transnational. The contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), is part of NIAID's clinical resource infrastructure to accelerate Phase 1 studies of promising clinical stage drugs or vaccines that address emerging and re-emerging infectious tropical diseases and bioweapon pathogens. The Phase 1B clinical study of SQ109 should be initiated in Q1 2009.

SQ-109 is a new diamine antibiotic intended to replace one or more of the current first-line anti-TB drugs and simplify patient therapy. SQ109 was granted U.S. FDA Fast Track designation and FDA/EMEA Orphan Drug Designation in 2007. SQ109 shows activity against drug sensitive and multi-drug resistant (MDR and XDR) Mycobacterium tuberculosis, the causative agent of TB. The Phase 1B study will assess safety and pharmacokinetics of multiple doses of SQ109 in healthy subjects.

"This is absolutely the best of both worlds for Sequella," commented Dr. Carol Nacy, Sequella CEO. "We again successfully competed for support from our most valued funding partner, NIAID, while retaining the capacity to work with the same industry-leading contract research organization, Quintiles Transnational, that conducted our first-in-human Phase 1A trial for SQ109.

The trial will be conducted at the Overland Park Quintiles Transnational Phase 1 facility in Lenexa, Kansas.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for diseases of epidemic pot
'/>"/>

SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
2. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
3. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
4. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
5. Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens
6. Novel Compound Shows Promise for Treatment of Alcoholism
7. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
8. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
9. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
10. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
11. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness ... Fitness Center by the Medical Fitness Association, a non-profit ... achieve their full potential. The Cadence Fitness & Health ... western suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... organiser UBM Live , a division of UBM ... CPhI Japan events line-up that is set to return ... March, 2012. The Pharmatech Japan event, which focuses on ... veterinary and medical industries, will join the Japan Pharma ...
... Pharmaceuticals, Inc. (Nasdaq: AUXL ) today announced ... Capital Global Healthcare Conference to be held March 13-14, ... Sargent, Vice President, Investor Relations and Corporate Communications, is ... its product pipeline at 8:00 a.m. ET on Tuesday, ...
Cached Medicine Technology:New Pharmatech Event to be Introduced Alongside CPhI and P-MEC Japan 2New Pharmatech Event to be Introduced Alongside CPhI and P-MEC Japan 3Auxilium Pharmaceuticals to Present at the 2012 Barclays Capital Global Healthcare Conference 2Auxilium Pharmaceuticals to Present at the 2012 Barclays Capital Global Healthcare Conference 3Auxilium Pharmaceuticals to Present at the 2012 Barclays Capital Global Healthcare Conference 4
(Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
(Date:4/17/2014)... therapy improves general blood flow and alleviates muscle ... researchers at the University of Illinois at Chicago. ... print in the Archives of Physical Medicine ... vascular function in people who had not exercised, ... of their level of physical activity. , Improved ...
(Date:4/17/2014)... of Canadians surveyed said they would participate in public ... of genetic conditions, only 80 per cent said they ... sequence their newborns, genomes.,Most newborns in North America have ... two of life in which a tiny amount of ... about five to 54 conditions, depending on the state ...
(Date:4/17/2014)... as the leading weapon against the deadly disease could ... research indicating it simply needs to be administered differently. ... cheap anti-malarial drug chloroquine in treating and preventing the ... half a million people each year around the world. ... to chloroquine, but research carried out at the Australian ...
(Date:4/16/2014)... Ariz. April 15, 2014 The Translational Genomics ... at their annual Founders Dinner for their support of ... event took place March 28 in Scottsdale. , Catherine ... Ivy Foundation, received TGen,s John S. McCain Leadership Award, ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... of interoperable Health Information Technology (HIT) will be ... the U.S. healthcare system," Yul D. Ejnes, MD, FACP, ... Health today. "Unfortunately, without adequate financial incentives, small ... technological curve." Dr. Ejnes, a member of the Board ...
... launches first of three-part series, MONTCLAIR, N.J., July ... the launch of an educational Webcast series on,chronic pain ... chronic pain sufferer, Nikki Stone. The first in the,three-part ... You Back" is available today at http://www.painawareness.org ., ...
... July 24 Colombia has appointed Dallas sports,chiropractor, Dr. ... medical team,during the upcoming Olympic Games in Beijing. Dr. ... worked with the Costa,Rican team for the 2007 Pan ... a privilege to bring the profession to an international ...
... BURLINGTON, Mass., July 24 Palomar Medical,Technologies, Inc. (Nasdaq: ... devices for hair removal and other cosmetic treatments, will,hold ... financial,results on Thursday, July 31, 2008 at 11:30AM Eastern ... 362-4831 at 11:20 AM Eastern Time on,that day. The ...
... The University of Queensland is helping to increase medical ... advanced clinical training facility. , UQ,s Rural Clinical ... and Learning Centre to its portfolio, with space to ... adjacent to the Toowoomba Base Hospital in West Street, ...
... new research facility is planned to enable unprecedented understanding ... shape human behaviour. The 28.5 million funding comes ... Universities and Skills (DIUS), and will be used for ... be a collaboration between the Economic and Social Research ...
Cached Medicine News:Health News:ACP says Medicare should increase payments for physicians that use HIT to improve quality 2Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 2Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 3Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 4Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 5Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 6Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 7Health News:Colombia Appoints Dallas Chiropractor to Olympic Team 2Health News:Palomar Medical Technologies to Host Second Quarter 2008 Financial Results Conference Call and Webcast on July 31, 2008 2Health News:New $4.2m UQ medical center to boost rural doctor numbers 2Health News:£28.5M investment for groundbreaking new research facility 2
... Acid is a non-irritating rapid exfoliator. Lactic Acid ... to peel and exfoliating agents in skin care ... other exfoliators for a long period and want ... occurring human metabolite, and combined with the chemical ...
... is available in two innovative formulations: Level ... active). The Level I (40% active) formulation ... extract, which DCL scientists have identified and ... and calm the skin while the beneficial ...
... CosmoDerm and CosmoPlast are dermal fillers ... acne scars and other soft tissue contour ... of the lip border. The collagen in ... dermal tissue that is grown under controlled ...
... is a gel of ... species of bacteria, chemically ... suspended in phosphate,buffered saline ... and concentration of 20 ...
Medicine Products: